International Journal of Advance and Applied Research
www.ijaar.co.in
ISSN – 2347-7075 Impact Factor – 7.328
Peer Reviewed Bi-Monthly
Vol.10 No.1 September – October 2022

ROLES OF THE IMMUNE SYSTEM IN CANCER: FROM TUMOR INITIATION TO METASTATIC PROGRESSION

Ms. Dingankar Niha Noormohammad Shabana[1] & Dr. Vinod Vaze[2]
[1]Ph.D. Research Scholar, Department of Computer Science and Engineering, Shri. JJTU, Rajasthan, India
[2]Ph. D. Guide, Department of Computer Science and Engineering, Shri. JJTU, Rajasthan, India
Corresponding Author - Ms. Dingankar Niha Noormohammad Shabana
DOI - 10.5281/zenodo.7539725

Abstract

The presence of provocative resistant cells in human growths brings up a principal issue in oncology: How do disease cells keep away from the obliteration by safe assault? On a fundamental level, growth improvement can be constrained by cytotoxic natural and versatile resistant cells; notwithstanding, as the cancer creates from neoplastic tissue to clinically distinguishable cancers, disease cells develop various components that impersonate fringe safe resilience to keep away from tumoricidal assault. Here, we give an update of late achievements, bringing together ideas, and future difficulties to concentrate on growth related insusceptible cells, with an accentuation on metastatic carcinomas.

Keywords: *Immune System, Cancer, Tumor, Immune Cells*

Introduction:

Malignant growth stays a significant reason for death around the world, and, with a maturing populace, its yearly cost of 8.2 million is simply expected to expand [1]. In this regard, carcinomas can be comprehensively partitioned into two gatherings: metastatic (the chief reason for malignant growth related passings) and nonmetastatic. Customarily, metastasis has been considered to happen in later phases of malignant growth movement; be that as it may, aggregating proof has additionally portrayed metastatic scattering during early cancer arrangement. During metastasis, dispersing malignant growth cells escape from essential cancers and procure cell characteristics that permit them to travel and colonize far off organs [3].

Essential and metastatic cancers are mind boggling biological systems made out of neoplastic cells, extracellular framework (ECM), and "embellishment" nonneoplastic cells, which incorporate inhabitant mesenchymal support cells, endothelial cells, and penetrated provocative insusceptible cells. Crosstalk between malignant growth cells and embellishment cells energizes and shapes cancer improvement. During cancer development, tissue engineering advances into an exceptionally particular microenvironment portrayed by an undermined ECM and persistent irritation [4]. Malignant growth-related aggravation, which is available at various phases of tumorigenesis, adds to genomic

precariousness, epigenetic alteration, acceptance of disease cell multiplication, improvement of malignant growth hostile to apoptotic pathways, excitement of angiogenesis, and, in the long run, malignant growth scattering [5]. Studies during the most recent twenty years have exhibited that provocative insusceptible cells are fundamental players of malignant growth-related aggravation. Endeavors have zeroed in on understanding what resistant cells mean for growth destiny in various phases of sickness: early neoplastic change, clinically distinguished cancers, metastatic scattering, and restorative mediation. In this survey, we center around late outcomes, bringing together ideas, cutoff points, and prospects difficulties in concentrating on malignant growth related provocative cells, with an accentuation on metastatic carcinomas.

Cancer-Related Inflammatory Conditions:

Beginning around 1863, when Virchow previously conjectured that malignant growth creates as the result of unsettled aggravation [6], growth related irritation has been critical to forming our cutting-edge comprehension of disease movement (Fig. 1). Today, it is acknowledged that persistent irritation is a basic sign of malignant growth, with something like 25% of diseases related with it [7], and conceivable fundamental causes incorporate microbial contaminations, autoimmunity, and insusceptible liberation. For instance, human papilloma infections (HPVs) instigate aggravation and are answerable for 90%-100 percent of every single cervical malignant growth. Additionally, persistent contamination with Helicobacter pylori hoists the gamble for gastric malignant growth. Furthermore, the resistant liberation seen in provocative entrail sickness increments colorectal malignant growth occurrence [8]. The nonhuman type of sialic corrosive — N-glycolylneuroaminic corrosive (Neu5Gc) — in red meat can be integrated into human tissue and select provocative cells. In this sense, diet might assume a causal part in enlistment of malignant growth related irritation [9]. Significantly, tobacco and corpulence, the two of which instigate poor quality aggravation, bring about raised dangers of malignant growth [10] this proof recommends that most of malignant growths is related with unsettled aggravation.



Figure 1. Chronic inflammation is a necessary consequence of cancer progression. Different inflammatory conditions can lead to neoplastic transformation.

While persistent aggravation plays a significant part in malignant growth, less is had some significant awareness of the effect of intense irritation on cancer movement. For instance, prompting intense irritation locally in the bladder with an immunization containing a constricted Mycobacterium bovis strain effectively treats squamous malignant growth of the bladder [11]. Consequently, with the penetration of leukocytes and resulting aggravation, the effect from provocative middle people can both start and, in specific cases, dispose of growth cells and forestall growth advancement

[12]. This double job of aggravation additionally becomes apparent in the facility, where immunodeficient patients are more frequently determined to have malignant growth [13].

Whether irritation is a reason or an outcome, the growth microenvironment (TME) is compromised, setting off a resistant provocative reaction, and histopathological examinations give proof to the presence of natural and versatile safe cells in most human growths, which are described as highlights of disease movement [14].

Role of Inflammatory Cells during Cancer Progression:

The presence of growth-related provocative cells in cancers brings up a significant issue, which would one say one is of the main difficulties in oncology: How do disease cells stay away from obliteration by the resistant framework? Since provocative cells were first seen in quite a while, much exertion has been put resources into better figuring out the mind-boggling job of fiery cells in carcinomas. It is at present acknowledged that a distorted intrinsic and versatile insusceptible reaction adds to tumorigenesis by choosing forceful clones, instigating immunosuppression, and invigorating malignant growth cell multiplication and metastasis [15, 16]. During the beginning phases of growth advancement, cytotoxic insusceptible cells like regular executioner (NK) and CD8+ Lymphocytes perceive and dispense with the more immunogenic disease cells. This first period of disposal chooses the multiplication of malignant growth cell variations that are less immunogenic and subsequently imperceptible to insusceptible identification. As neoplastic tissue develops into a clinically distinguishable cancer, various subsets of provocative cells influence growth destiny. For instance, elevated degrees of growth penetrated Immune system microorganisms correspond with great visualization in numerous strong diseases then again, elevated degrees of macrophage penetration correspond with a more regrettable visualization [17]. Here, we survey the significant perspectives and various features of malignant growth-related insusceptible cells, zeroing in on movement from cancer commencement to metastatic colonization.



Figure 2. The balance between effector and tolerogenic immune response dictates tumor fate.

Macrophages:

Macrophages are intrinsic insusceptible cells that separate from circling traditional monocytes after extravasation into tissues. Upon separation, macrophages are prepared to detect and answer contaminations and tissue wounds, assuming a key part in tissue homeostasis and fix. As significant drivers of persistent malignant growth-related aggravation, their contribution has been portrayed in each step of disease movement, from early neoplastic change all through metastatic movement to treatment obstruction. In oncological patients and preclinical exploratory models, high-grade growth related macrophages (Caps) correspond with

unfortunate visualization and diminished generally speaking endurance [18].

Initiated macrophages are alluded to as either proinflammatory ("M1 type," driven by LPS and IFNγ) or mitigating ("M2-type," driven by IL-4 or IL-13) [19]. During carcinogenesis, antitumor macrophages show a M1-like polarization that assumes a significant part in the disposal of more immunogenic malignant growth cells. As the cancer advances, the TME inspires a M2-like polarization of Caps that is protumorigenic. Caps advance growth movement in various ways, like animating angiogenesis and lymphangiogenesis, invigorating both disease cell multiplication and epithelial-mesenchymal progress, restricting the viability of treatments, redesigning the ECM, advancing metastasis, and actuating immunosuppression of hostile to cancer effector resistant cells [20]. In like manner, Caps discharge cytokines like IL-10 [21] and TGF-β (McIntire et al. 2004) that instigate immunosuppression, debilitating the movement of effector Lymphocytes and restraint of dendritic cell (DC) development (Rubtsov et al. 2008). Caps additionally straightforwardly invigorate disease cell multiplication through the discharge of epidermal development factor (EGF) advance growth angiogenesis by vascular EGF (VEGF) discharge and redesign the ECM by discharging metalloproteinases (MMPs). For instance, macrophage-determined MMP-9 advances tumorigenesis and angiogenesis [22].

In spite of the fact that Caps for the most part play protumorigenic jobs, they can likewise some of the time apply hostile to tumoral jobs. For instance, nonclassical NR4A1+ watching monocytes that, in consistent state conditions, are situated in the microvasculature of various organs restrain lung metastasis in MMTVPyMT mice by direct acceptance of NK cell enlistment to the metastatic site. Furthermore, Caps intercede the viability of the counter growth and antimetastatic impacts of the histone deacetylase inhibitor TMP195, which reconstructs Hat to an exceptionally phagocytic aggregate [23].



Figure 3. Roles of innate immune cells in metastatic cancers.

This is trailed by ensuing capture of bone marrowderived macrophages and neutrophils in the liver, coming about in a prometastatic impact, reversible by macrophage removal [24].

Neutrophils:

Neutrophils are perceived as central participants during aggravation. They are among the principal insusceptible cells to be enlisted to harmed tissue, where they can dispense with microorganisms and regulate aggravation by instruments like phagocytosis, discharge of antibacterial proteins, store of neutrophil extracellular snares (NETs), and exocytosis of protease-containing granules [25]. In disease patients, elevated degrees of growth-related neutrophils (TANs), elevated degrees of neutrophilia, and additionally high neutrophil/lymphocyte proportions have been related with an unfavorable visualization in various

malignances [26]. Like the M1/M2 aggregate of macrophages, it has been recommended that TANs exist in two polarization states, called "N1" and "N2," to portray protumor and hostile to growth populaces, separately [27]. This worldview is as yet a question of discussion because of the absence of explicit markers to distinguish these two populaces. Notwithstanding, obviously TANs show utilitarian heterogeneity. The enlistment of TANs to the TME is believed be interceded for the most part by CXCR2 ligands like CXCL1, CXCL2 and CXCL5 [28] discharged by malignant growth and stromal cells; TGF-β has additionally been related with enrollment and reconstructing to protumor TANs [29].

Interestingly, TANs are remembered to add to beginning aggravation during malignant growth commencement and movement. In a Kras-driven lung adenocarcinoma mouse model, IL-17-responsive TANs advance cancer development [30]. Likewise, neutrophil elastase goes about as a powerful elastolytic chemical that, when discharged in a site of irritation, advances growth cell intrusion, angiogenesis, and disease cell multiplication. Additionally, TANs add to the growth angiogenesis by the discharge of MMP9 and VEGF in hereditary mouse models of pancreatic and colon disease. In gastric malignant growth, TANs actuate direct immunosuppression in White blood cells by PD-L1 articulation prompted by cancer determined granulocyte macrophage-CSF (GM-CSF). A populace of cells phenotypically and morphologically like neutrophils, called polymorphonuclear myeloid-determined silencer cells (PMN-MDSCs), has been distinguished in malignant growth patients and preclinical models. The presence of PMN-MDSCs in growths is related with acceptance of persistent aggravation and antigen-explicit resilience by Immune system microorganisms. Utilizing the MMTV-PyMT transgenic bosom disease model, we portrayed that the development of cancer determined G-CSF during cancer movement instigates the methodical separation and initiation of PMN-MDSCs, described by CD11b+ Rb1lo Ly6G+.

T cells:

White blood cells are parts of the versatile insusceptible framework that go about as orchestrators and effectors of insusceptibility. Contingent upon the immunological setting, White blood cells can procure utilitarian and effector aggregates whose movement has direct provocative or mitigating outcomes. As the second most successive resistant cell type found in human growths other than Caps, Immune system microorganisms are broadly concentrated on in different disease types. During the beginning phases of growth commencement, assuming an adequate number of immunogenic antigens are delivered, credulous White blood cells will be prepared in the depleting lymph hubs, trailed by their corresponding enactment and relocation to the TME. From that point, they mount a defensive effector insusceptible reaction, dispensing with immunogenic malignant growth cells. Histopathological examinations of human cancers show that growth related Immune system microorganisms stretch out past the obtrusive edge of the cancer and furthermore prevail in its hypoxic center. An elevated degree of Immune system microorganism penetration in cancers is related with a positive visualization in melanoma and bosom, lung, ovarian, colorectal, renal, prostate, and gastric malignant growth.

CD8+ Immune system microorganisms are the most unmistakable

enemy of cancer cells. After preparing and actuation by APCs, the CD8+ Immune system microorganisms separate into cytotoxic T lymphocytes (CTLs) and, through the exocytosis of perforin-and granzyme-containing granules, apply a proficient enemy of tumoral assault, bringing about the immediate obliteration of target cells. In the meantime, the CD4+ T partner 1 (Th-1)- interceded enemy of tumoral reaction — through discharge of high measures of proinflammatory cytokines like IL-2, TNF-α, and IFN-γ — advances not just Immune system microorganism preparing and enactment and CTL cytotoxicity yet additionally the counter tumoral movement of macrophages and NK cells and a general expansion in the introduction of growth antigens. The presence of cancer penetrating CD8+ Immune system microorganisms and Th-1 cytokines in growths corresponds with a positive visualization as far as generally speaking endurance and a sickness free endurance in numerous malignancies [33].

Cross-Talk Between Immune Cells Sculpts The Response To The Tumor:

A perspective that has gotten less consideration is the crosstalk between various insusceptible cells inside the TME and what it means for the result of the ensuing invulnerable reaction. There is developing proof that growth related resistant cells act in show to both control and advance the cancer arrangement. In this sense, during the period of disposal, NK cells apply serious areas of strength for a job; discharge of CCL5 and XCL1 by NK cells advances the enrollment of customary DCs (cDCs) to the TME, bringing about expanded preparing and enactment of new collections of hostiles to cancer Lymphocytes, invigorating the general effector resistant reaction. Furthermore, the corresponding exchange between NK cells, effector Immune system microorganisms, and hostile to growth macrophages by the discharge of IFN-γ and TNF-α in the cancer site supports the separation of CTLs, increments macrophage phagocytosis, expands the enrollment of cytotoxic cMET+ neutrophils, and improves the cytotoxic capacity of NK cells. Dectin-1, an example acknowledgment receptor on macrophages and DCs, perceives N-glycan structures on growth cells, which initiate the IRF5 pathway liable for improving the killing limit of NK cells. Besides, CX3CR-1+ watching monocytes restrain metastatic movement through the enlistment of NK cells to the metastatic site, and afterward NK cell-determined IFN-γ reconstructs macrophages into a tumoricidal effector macrophage state.

When the cancers have gotten away from introductory tumoricidal insusceptibility, they go through various methodologies that influence the equilibrium toward invulnerable resilience, with the Caps and growth related Tregs as key orchestrators of this interaction, as they hose the impact of intrinsic and versatile effector resistant cells at different levels and through various instruments. For instance, Caps and Tregs support an insusceptible open minded TME by discharge of invulnerable suppressive particles like IL-10, TGF-β, and prostaglandins; they additionally restrain the emission of IL-12 by DCs, keeping away from the mounting of a Th-1 reaction and barring NK and effector Immune system microorganisms. As of late, a blend immunotherapy — including a growth antigen focusing on neutralizer, a recombinant interleukin-2 with a drawn-out half-life, hostile to PD-1, and a

Lymphocyte immunization — productively disposed of laid out enormous metastatic growths in different disease models; resulting examination showed that the viability was reliant upon a coordinated reaction of both natural and versatile resistant cells. This information further features the significance of treatments intended to invigorate a coordinated insusceptible effector reaction.

Cancer Heterogeneity And Anti-Tumor Immuno surveillance:

Investigation of human essential and metastatic cancers has shown elevated degrees of genomic, phenotypic, and antigenic heterogeneity which add to treatment disappointment and infection movement. This represents an exhausting clinical and specialized challenge. Different instruments have been proposed to make sense of intratumor heterogeneity: Genomic precariousness, various leveled association emerging from starting malignant growth foundational microorganisms and particular tension forced by the insusceptible framework probably influence antigen heterogeneity of the cancer. Through malignant growth insusceptible altering, the invulnerable framework dispenses with the more immunogenic disease cells, in this manner advancing the improvement of clonal cancers and consequently diminishing the heterogeneity. Interestingly, the absence of insusceptible determination probably expands the neoantigen heterogeneity. Ongoing examination of neoantigen heterogeneity in growth tests from cellular breakdown in the lungs and melanoma patients exhibited that patients with clonal cancers (~78% of clonality) are more defenseless to Immune system microorganism assault and have a more delicate growth designated spot restraint contrasted and more heterogeneous growths (~8% of clonality). Additionally, examination of various areas of heterogeneous growths showed various degrees of antigen-explicit CD8+ Immune system microorganisms in various cancer districts. Expansions in the mutational weight and heterogeneity of neoantigens in vivo as well as the preparing of new enemy of cancer Immune system microorganism collections result from the inactivation of the DNA fix framework in colorectal, bosom, and pancreatic cell lines. Strangely, growths with high neoantigen trouble correspond with great visualization in cellular breakdown in the lungs patients treated with hostile to PD1. As genomic cancer heterogeneity increments, so too does the likelihood of subclonal ages getting away from insusceptible assault. In this sense, metastatic movement and treatment obstruction for the most part continue from uncommon clones in essential growths. Predictable with this view, a profound examination of intrapatient metastases in a patient with ovarian malignant growth showed that relapsing metastatic cancers were related with a resistant penetrate described by CD4+ and CD8+ Immune system microorganisms and higher growth change and neoepitope load contrasted and advancing sores that are related with White blood cell prohibition. This contextual investigation gives proof of the clinical effect of the connection between cancer heterogeneity and hostile to growth insusceptible reconnaissance. It is muddled whether the malignant growth heterogeneity saw in patients is the final product the resistant framework's powerlessness to stop cancer movement or whether the mutational weight elevates heterogeneity that prompts safe avoidance. Moreover, the advancing transformation

trouble, the particular tension of chemotherapy, and the quick turnover of provocative cells inside the essential and metastatic growth, related to the nonuniform appropriation of resistant cells all through the cancer, reasonable advance differential specific tensions in dissimilar growth districts, considering the improvement of heterogeneous growths. The progress of current immunotherapies relies upon the capacity of the insusceptible framework, especially White blood cells, to perceive and dispose of growths with multiclonal or subclonal neoantigens. These discoveries feature the significance of better comprehension the mind boggling connections between malignant growth cells and insusceptible assault and how these connections drive the improvement of disease heterogeneity.

Conclusion:

Immunological investigations during the most recent twenty years have responded to numerous significant inquiries connected with the causal connection between persistent aggravation and carcinogenesis. Today, oncoimmunology is a field of quick development and development. The improvement of new preclinical models and high-goal innovations has given in any case difficult to reach information, opening up thrilling new roads, exemplified by how focusing on the resistant framework to battle malignant growth is turning into a reality, as confirmed by the overall progress of current immunotherapies. There obviously stays a lot of work to be finished, and there are many difficulties to confront. In the first place, it will be important to foster high-constancy immuno-adequate preclinical models that consolidate the cell and antigenic heterogeneity of malignant growth cells saw in patients. Second, a superior comprehension of the resistant cross-talk that outcomes in tumoricidal insusceptibility will prompt the levelheaded plan of designated treatments that will work on the effectiveness of the ongoing immunotherapies. Third, since >90% of cancerassociated passings result from improvement of metastasis (Jemal et al. 2008; Siegel et al. 2016), we really want to confirm whether the information produced in essential growths can be utilized to construe sub-atomic bits of knowledge into metastatic cancers. Last, a critical exertion into more deeply studying insusceptible reconnaissance related with less-contemplated metastasic destinations, including liver, bone, and cerebrum metastasis, is required.

References:

1) Abraham D, Zins K, Sioud M, Lucas T, Schafer R, Stanley ER, Aharinejad S. 2010. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer 126: 1339–1352.
2) Allaoui R, Hagerling C, Desmond E, Warfvinge CF, Jirstrom K, Leandersson K. 2017. Infiltration of γδ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer Biomark 20: 395–409.
3) Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al. 2010. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121–134.
4) Andrews DM, Sullivan LC, Baschuk N, Chan CJ, Berry R, Cotterell CL, Lin J, Halse H, Watt SV, Poursine-Laurent J, et al. 2012. Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the

licensing and activation of NK cells. Nat Immunol 13: 1171–1177.
5) Askeland EJ, Newton MR, O'Donnell MA, Luo Y. 2012. Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012: 181987.
6) Balkwill F, Mantovani A. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539–545.
7) Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, et al. 2013. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145: 166–175 e168.
8) Bedard PL, Hansen AR, Ratain MJ, Siu LL. 2013. Tumour heterogeneity in the clinic. Nature 501: 355–364.
9) Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, et al. 2011. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 17: 4558–4567.
10) Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
11) Nat Cell Biol 2: 737–744. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et al. 2012. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18: 1224–1231.
12) Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. 1991. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349: 329–331.
13) Boger C, Behrens HM, Kruger S, Rocken C. 2017. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy? Oncoimmunology 6: e1293215.
14) Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M. 2014. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515: 130–133.
15) Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. 2013. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 210: 2435–2466.
16) Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244–265.
17) Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis ESC. 2018. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172: 1022–1037.e14.
18) Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, Kumar R. 2010. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother 59: 303–312.
19) Cools-Lartigue J, Spicer J, Najmeh S, Ferri L. 2014. Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci 71: 4179–4194.

20) Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et al. 2015. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17: 816–826.
21) Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420: 860–867.
22) DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54–67.
23) DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, et al. 2011. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17: 1514–1520.
24) De Silva NS, Klein U. 2015. Dynamics of B cells in germinal centres. Nat Rev Immunol 15: 137–148. de Visser KE, Korets LV, Coussens LM. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411–423.
25) Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. 2016. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29: 587–601.
26) Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144.
27) Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646–674.
28) Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, Herrley E, Rasquinha N, McArdle S, Wu R, et al. 2015. Patrolling monocytes control tumor metastasis to the lung. Science 350: 985–990.
29) Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. 2000. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13: 265–276.
30) Headley MB, Bins A, Nip A, Roberts EW, Looney MR, Gerard A, Krummel MF. 2016. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531: 513–517.
31) Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. 2014. Predictive correlates of response to the antiPD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567.
32) Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, et al. 2018. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gutr 67: 1845–1854.
33) Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. 2016. Mouse models in oncoimmunology. Nat Rev Cancer 16: 759–773.